Skip Ribbon Commands
Skip to main content

Key Milestones

The National Heart Centre Singapore (NHCS) is dedicated to providing optimal care and outcomes through continuous advancement in patient care, education and training, and research

Learn more about our key milestones.

  • Boehringer Ingelheim partners with Enleofen in a signature biotech deal to research and develop drug therapies, which will help reverse inflammation and fibrosis in diseased organs. Enleofen is a spinout company from NHCS and Duke-NUS Medical School, under the SingHealth Duke-NUS Academic Medical Centre.
  • NHCS launched telemedicine initiatives, including telephone and video consultations, for a wide range of clinical care and services. The telemedicine services are offered to patients with stable conditions, and provides remote care with greater convenience to patients and their caregivers.
  • Researchers from NHCS identified a unique lean diabetic phenotype among Asian patients with heart failure. NHCS researchers together with Asia-wide investigators launched the Asian Diabetes Outcome Prevention Trial (ADOPT), a multinational clinical trial, to help prevent heart diseases in high-risk patients with diabetes.
  • Bayer and NHCS entered into a five-year collaboration agreement to set up a “Center of Excellence for Explorative Cardiovascular Studies”, with the aim of boosting patient-centricity in research and development (R&D) and improving treatment outcomes in cardiovascular disease management.
Understanding Blood Pressure and Hypertension

Understanding Blood Pressure and Hypertension

24 Nov 2021 | Murmurs (NHCS)
Enhancing medication safety for every patient

Enhancing medication safety for every patient

11 Oct 2021 | Stories from the Heart (NHCS)